Russian nuclear monopoly Rosatom to expand into domestic pharma business

5 March 2018

Russian nuclear monopoly Rosatom is expanding in the domestic pharmaceutical business through investing six billion roubles ($105 million) in the construction of a factory for the production of drugs for the treatment of cancer and autoimmune diseases, reports The Pharma Letter’s local correspondent.

The new factory will be built in the Moscow region. Implementation of the project will be carried out by Rosatom Healthcare, which is a specially established subsidiary of Rosatom.

Rosatom does not indicate the timing for the construction but, according to some sources close to the company, the project may be completed within the next four-to-five years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK